Lehman (LEH): When Will Fuld Show Us What's Really In His Hand?

Did he lie? Did he fib? Did he know? Do we care?

Accountability has not been part of the leadership equation here. Transparency was not part of the Fuld business model either. There is officially no love for the "Level 3 Asset" scheme, and now Fuld wants to sell the Street real estate and Neuberger Berman?

He may very well do that, and at the same time, the Street is selling his stock. Down another -13% today. That's an unlucky number. Luck may not save the day here anyway. Ever play ‘Monopoly’ against someone who is levered up and forced to sell assets?

  • LEH support? $11.35 looks like next stop
Chart courtesy of

Chart Of the Day: Macro vs. Earnings Season, Beware...

As another 2008 Earnings Season limps to a close, you'll find this chart as relevant as any other out there. Notice that we are exiting the 3rd earnings season (blue on the chart) of the year, and pay close attention to the path that the US market has taken post the previous two.

I know - everyone doesn’t "do Macro". But I also know … that everyone knows… that it matters.

If you are still levered up long, beware of this upcoming Macro Season.

(Chart by Andrew Barber, Director - Research Edge LLC)

Target (TGT) vs. WalMart (WMT): Who Thinks Cash Is King?

On their conference call this morning, Target (TGT) attempted to appease Bill Ackman by talking up their "buy back" program which will fabricate a Q4 earnings lift. This short term call is going to have negative long term ramifications.

Target bought back another $1.7B worth of stock (33.8M shares) at an average price just north of $50/share. I am initiating that price as my new stop loss level on the short side.

Below I have attached capital intensity charts for WMT and TGT. Pershing Square likes playing the levered long investing game. Unfortunately that shortsighted strategy was best served for years that are behind us now. The economic cycle has changed course. As cost of capital increases and access to capital tightens, we want to own prudent management teams that are cutting capex and holding cash in the bag for the rainy days that cometh.

*Full Disclosure: I remain long WMT and short TGT in our “Hedgeye Portfolio”
  • TGT
  • WMT
TGT Capex as % of Sales
WMT Capex as % of Sales

Daily Trading Ranges

20 Proprietary Risk Ranges

Daily Trading Ranges is designed to help you understand where you’re buying and selling within the risk range and help you make better sales at the top end of the range and purchases at the low end.

Cotton: Important Historical Context

Since July 31, cotton prices have wanted to do nothing but go down. One might say that it is simply a function of oil’s decline. This is, no doubt, a driver. But I don’t buy it in full. After having close to zero correlation for most of the year, both have slid meaningfully over the past few weeks. In fact, cotton has been higher beta than oil in recent weeks – a reversal of what we have seen in past cycles when they have correlated.

This is pretty important to me given that a material slide in cotton costs could ease the apparel industry’s supply chain strain for a brief while – which would cause me to evaluate where I stand on some of these names vis/vis horrible ‘trend’ and decent ‘trade’.

Leave it to my colleague Andrew Barber to find something in the commodity history books to explain this away. The analysis by Moore Research Center below shows how the seasonal nature of planting/harvesting cotton rather consistently flows through to the yy change in the price of the commodity.

The seasonally weakest time period over the past 33 years? You guessed it. Mid August. It is always tough for me to stomach that ‘seasonal trading charts’ like this have the right to exist. We’ll see if this continues in the coming weeks.

WRC: Phelps is History

I know it seems like every day I am throwing out another reason why not to like Warnaco. I’m not trying…the facts simply keep rolling in. The latest has to do with none other than Michael Phelps and Nike.

Phelps created a brand for himself faster than any human I have ever seen. Everything from inspiration, hard work, team focus, and sheer determination (not to mention 12k calories per day of carb loading). Product endorsers are chasing him like wildfire. Heck, Mrs. Phelps even took Donovan McNabb’s mother’s job as a soup pitch-mom.

Speedo currently endorses MP for swimwear and goggles. That’s going to change, in my humble opinion.

Let’s assemble a little narrative…

For the first time since I can remember, Nike bowed to avert a PR disaster and allowed its swimmers wear Speedo suits at the games. A wise move. Speedo’s product was superior. If Nike athletes lost, then it would be blamed on product. Not good. If they swam in Speedo and lost, then that’s ammo for Nike to bash the competition.

Either way, I would not want to be part of the swim product/marketing team at Nike leading up to the games. I definitely would not want to be part of the team as Michael Phelps garnered more attention than almost any athlete in modern Olympic history. Nike hates to lose.

What comes next? Phelps almost loses gold in the 200 meter butterfly as his Speedo goggles failed and filled with water.

Phelps goes on to conquer the swimming world, and US hearts alike. This missed product/marketing opportunity on a world stage coincided with Liu Xiang (Chinese hurdler, National hero, and Nike guy) failing to compete in his race. It also synchs with non-Olympic developments, such as Lance Armstrong’s wind-down as a Nike torchbearer, Tiger’s injury, and the seemingly unstoppable Federer being handed some high-profile losses. Granted – Roger lost to another Nike athlete (Rafael Nadal), but the rivalry has not been the brand builder one might have thought. Nike is probably thinking that it needs new blood.

Combine the fact that it wants to crush Speedo with the need for someone who transcends a single sport (i.e. can be on the cover of SI, Time, and Men’s Health all at once) and you’ve got the perfect Nike pitchman.

The math here is pretty simple. Nike has about $2.3 billion (with a B) in SG&A. Warnaco spends about $100mm, with less than 10% going to Speedo. Nike could pay $10mm annually in a heartbeat. For Speedo to match, it would cost 15% of EPS. Nike’s toll would be only 0.3% of EPS. This battle would be the equivalent of the US invading Aruba.

The bottom line here is that my confidence level is quite high that Nike is going to either a) Make Warnaco/Speedo pay-up meaningfully to retail Phelps, or b) lure away WRC’s highest profile endorsee.

LDG, Part IV: Levering Up To Buy An Asset Headed Into A Secularl Slowdown?

Pharmacy revenue growth appears to be in the grip of a secular slowdown that has no end in sight. While the "The Aging Baby Boomers" are a source of comfort to many investors, a closer look at the individual components that drive pharmacy revenues, suggest just the opposite, a slowing demand curve.

New drug approvals, unit inflation, and insurance coverage together point to tougher times for the pharmacy supply chain. Sum of the parts calculations place the low end of pharmacy revenue growth at 1% while putting an upper limit on growth at 3.5%, under the most favorable conditions.

Using the most recent data available from the National Health Expenditures Survey of 2004, which details per capita spending on pharmaceuticals, together with the population forecast from the US Census Bureau, total prescription dollar growth will remain at the moribund rate of 1.5% or lower for the foreseeable future.

New products from the Pharmaceutical Industry have not kept pace according the FDA. Whether this is a tougher, more risk-averse FDA, or bad decisions by R&D executives, the pace of innovation has been declining for over a decade.

Prescription inflation is slowing according to the CPI ( While generic introductions affect the shape of the curve, it appears the Pharmaceutical Industry has entered a new phase of lower pricing power. Lower unit inflation for prescriptions directly affects same store comps, but also slows the rate of change in the spread between wholesale acquisition costs and reimbursement for the pharmacy.

According to the Kaiser Family Foundation, a 1% change in the unemployment rate creates 1.1M uninsured individuals and increases Medicaid rolls by 1.0M, by law the lowest priced pharmaceutical buyer. Through 2006, the ranks of the uninsured were already climbing. With 154.6M in the civilian workforce, further increases in unemployment could represent a 50 to 100bps drag on pharmacy alone.

Tom Tobin
Managing Director

Hedgeye Statistics

The total percentage of successful long and short trading signals since the inception of Real-Time Alerts in August of 2008.

  • LONG SIGNALS 80.47%
  • SHORT SIGNALS 78.68%